“vertex-pharmaceuticals” Archives

in
Entry Author Date Location
Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects 10/15/20 Boston
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More 10/09/20 National
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug 10/08/20 National
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More 09/18/20 National
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More 09/04/20 National
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases 08/26/20 Boston
Yumanity to Merge With Proteostasis to Advance Neuro Drug Pipeline 08/24/20 Boston
Kymera Therapeutics Unveils IPO Pitch for Protein Degradation 07/31/20 Boston
Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership 07/09/20 Boston
Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments 05/26/20 San Diego
Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More 05/01/20 National
Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic 03/12/20 Boston
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic 02/18/20 Boston
Global Blood’s Sickle Cell Drug Wins FDA Approval Ahead of Schedule 11/25/19 San Francisco
Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More 11/22/19 National
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More 11/08/19 National
Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More 10/25/19 National
Vertex Stock Up on Quick FDA OK For 3-Drug Cystic Fibrosis Therapy 10/22/19 Boston
Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More 10/04/19 National
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone 09/06/19 National
Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes 09/03/19 Boston
White House Floats Canadian Import Plan But Excludes Many Costly Drugs 07/31/19 National
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More 07/26/19 National
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles 07/25/19 Boston
Vertex Pharma Shells Out $420M to Move Into Muscular Dystrophy 06/07/19 Boston
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More 05/31/19 National
Vertex Selects Drug Combo, a Potential Therapy for 90% of CF Patients 05/30/19 Boston
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More 05/17/19 National
Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera 05/15/19 Boston
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More 04/05/19 National
Page 1 of 14 next page »